Contribute Try STAT+ Today

As the Biden administration begins setting priorities, the Federal Trade Commission is poised to take a tougher stand on some pharmaceutical industry practices, given the potential for anti-competitive behavior to influence prescription drug prices.

The anticipation is fueled by two issues that have gained considerable attention in recent years. One has been notable dissent by two agency commissioners — both of whom are Democrats — over merger reviews. And the other is growing concern over the extent to which rebates paid by drug makers for favorable insurance coverage may be choking competition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.